Current status of low‐density lipoprotein cholesterol for primary prevention of coronary artery disease in late‐stage elderly persons with type 2 diabetes mellitus: A retrospective, single‐center study

Abstract

Aims/Introduction The importance of low‐density lipoprotein cholesterol (LDL‐C) in the primary prevention of cardiovascular disease has recently been reported in the population aged ≥75 years with hypercholesterolemia. Therefore, the current status of LDL‐C management for primary prevention of coronary artery disease in patients aged ≥75 years with type 2 diabetes mellitus was investigated. Materials and Methods A total of 124 patients aged ≥75 years who had type 2 diabetes mellitus, but no coronary artery disease, were investigated. The patients' background characteristics, LDL‐C, glycemic status, ankle‐brachial index and cardio‐ankle vascular index were compared between patients taking and not taking LDL‐C‐lowering agents, such as hydroxymethylglutaryl‐CoA reductase inhibitors (statins) and ezetimibe. The details of the antihyperlipidemic and antidiabetic agents used in the present study were also examined. Results LDL‐C was significantly lower in patients taking LDL‐C‐lowering agents (LDLCLT[+]) than in patients not taking them (LDLCLT[−]), although LDL‐C was maintained <120 mg/dL in both groups (93.0 mg/dL vs 102.1 mg/dL). Approximately half of the cases in the LDLCLT(+) group received moderate‐intensity statins, with pitavastatin being the most prescribed statin. Glycated hemoglobin was significantly lower in the LDLCLT(+) group than in the LDLCLT(−) group (6.9% vs 7.3%). Sodium‐glucose transporter 2 inhibitors were more frequently used in the LDLCLT(+) group than in the LDLCLT(−) group. The ankle‐brachial index/cardio‐ankle vascular index did not differ between the groups. Conclusion Low‐density lipoprotein cholesterol was properly managed for primary prevention of coronary artery disease in patients aged ≥75 years with type 2 diabetes mellitus regardless of the presence or absence of LDL‐C‐lowering agents.

Comparison of Pairwise Venous and Fingertip Plasma Using Quantitative Proteomics Based on Data-Independent Acquisition

“…Apolipoproteins are functional blood proteins involved in lipid homeostasis . They, therefore, reflect an individual’s metabolic status, and some of them are classical markers of cardiovascular risk and metabolic disorders such as diabetes. − We quantified 15 apolipoproteins (APOA1, APOA2, APOA4, APOB, APOC1, APOC2, APOC3, APOC4, APOD, APOE, APOF, APOH, APOL1, APOM, and LPA) in VP and FP of 12 individuals. The abundance of 15 proteins in paired VP and FP was the same basically both in the discovery and validation cohorts (Figure C and Supporting Information Figure S3C).…”

Combined Effects of Obesity and Dyslipidaemia on the Prevalence of Diabetes Amongst Adults Aged ≥45 Years: Evidence from a Nationally Representative Cross-Sectional Study

“…Observations confirmed the putative utility of dyslipidaemia in CVD risk prediction in individuals with diabetes [23]. Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor that may increase the risk of diabetes [24,25]. Obesity is the most common nutritional disorder worldwide, and it is one of the major risk factors for atherosclerotic CVD [26].…”